Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects.
about
Arginine Vasopressin and Copeptin in PerinatologyInteractions of the human cardiopulmonary, hormonal and body fluid systems in parabolic flight.Association of HPA axis hormones with copeptin after psychological stress differs by sexShort-Term Influence of Radiofrequency Ablation on NT-proBNP, MR-proANP, Copeptin, and MR-proADM in Patients With Atrial Fibrillation: Data From the Observational SMURF StudyUrine Concentrating Capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy Patients with Renal Impairment.Modern peptide biomarkers and echocardiography in cardiac healthy haemodialysis patients.The Circadian Rhythm of Copeptin, the C-Terminal Portion of Arginine Vasopressin.Circulating levels of copeptin, a novel biomarker in pre-eclampsia.Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patientsA copeptin-based classification of the osmoregulatory defects in the syndrome of inappropriate antidiuresisNormalization of elevated cardiac, kidney, and hemolysis plasma markers within 48 h in Mexican Tarahumara runners following a 78 km race at moderate altitude.Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney diseasePotentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease.Hyponatremia and anti-diuretic hormone in Legionnaires' disease.Copeptin testing in acute myocardial infarction: ready for routine use?Comparison of the temporal release pattern of copeptin with conventional biomarkers in acute myocardial infarction.Copeptin is associated with kidney length, renal function, and prevalence of simple cysts in a population-based study.Copeptin as an Indicator of Hemodynamic Derangement and Prognosis in Liver Cirrhosis.Copeptin, Insulin Resistance, and Risk of Incident Diabetes in Older Men.Copeptin Predicts Mortality in Critically Ill Patients.Cardiorenal biomarkers in acute heart failure.Effect of increased water intake on plasma copeptin in patients with chronic kidney disease: results from a pilot randomised controlled trial.Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohortCopeptin: a new and promising diagnostic and prognostic markerHypertension in mice with transgenic activation of the brain renin-angiotensin system is vasopressin dependentChanges in copeptin and bioactive vasopressin in runners with and without hyponatremiaPlasma Copeptin, AVP Gene Variants, and Incidence of Type 2 Diabetes in a Cohort From the Community.MDMA Impairs Response to Water Intake in Healthy VolunteersCopeptin and the risk of incident stroke, CHD and cardiovascular mortality in older men with and without diabetes: The British Regional Heart Study.Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome.Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria.Copeptin and its potential role in diagnosis and prognosis of various diseases.Copeptin: a biomarker of cardiovascular and renal function.Heart failure biomarkers.The use of biomarkers in the patient with heart failure.Novel biomarkers for heart failure.Quench the thirst: lessons from clinical thirst trials.Copeptin as a biomarker in heart failure.Pitfalls and opportunities in multidisciplinary research about nocturia in adults.Novel biomarkers predicting cardiac function after acute myocardial infarction.
P2860
Q26741093-27D96CFF-C7EB-4959-B687-A2F28D62AAF0Q30577964-E0F1C84D-0677-41A8-BE74-578EF808CCCEQ30693052-4B1E951B-8F2A-4D4C-8D13-496C368B630AQ31131029-4FB22065-537F-45DA-9BCA-288E09865628Q31154416-70ECF6B8-2A61-4045-99F3-0A300FEB4C98Q33743502-EC294F60-0D83-426E-9C88-C586A1E149FEQ33800762-2BF46228-8094-4B1C-A6B7-6A04B7A9B9B3Q33875627-497559FA-D1C8-4694-A346-CDD9456EBBC0Q34124758-3B97A02D-25A2-4BCD-A7D9-AD79B09C53ABQ34260031-4A28A4A0-77DA-45A1-978A-5B7EA3C2308AQ34541089-87CC7F45-E663-4BCC-AE74-7570ED5FF65EQ34639667-36E2AD69-6AA2-44A0-9153-EF5A1501C657Q34858052-ED9D9F73-4560-4A08-B259-6E2567B29006Q35065229-3505C4A2-29B8-444F-BF56-192F991CA83AQ35556651-D32C14AF-1EB0-4F6E-93A8-E948DDC84B29Q35569452-5C5E84F5-EDBD-4A2E-BBCE-6CC650A971CCQ35658585-8DBFDD8E-BECD-43C6-8FE8-9F5571954E4DQ35778155-437BC9B2-B88A-4078-89A3-33CBB470DDF3Q36060397-653EBEAB-DE50-442A-84C3-8E67286399B1Q36258947-0F108486-30CB-4E64-8012-F33B4640A60DQ36313675-3F65F242-90FC-4C93-BC50-9AF84EEFFE9CQ36329310-E5CA4EF8-38DA-4323-A09A-AD7334F0A202Q36616057-5951C3B2-5CCE-4EDE-AC3C-61C648AE1453Q36748907-ABAB4C73-4C82-419B-B886-74145220607EQ36838219-7A265BCE-36DC-493F-BAF0-1C0075C6B220Q36949164-66F6F812-D10C-4AC4-95D4-3780D8A90EE8Q36965316-DA804A56-589C-4232-817D-A0F9829CA005Q37043838-531F77B6-6DE6-4EF5-8050-086A224D184DQ37143797-48E50611-0E91-4BCD-B031-A1BC726E7E14Q37257539-B323533A-EC35-4D58-9C82-9AF0BA088478Q37278044-243F1C00-ADA2-4A34-BD84-0F918C5D7AC0Q37508425-9A551A2B-AF2B-4A32-AA28-59F279E44B73Q37775088-0573A787-CE70-4BB3-B4A2-E44E3ED24181Q38100647-D2D16B18-BA70-462E-88E3-2B66BCF429F9Q38104269-0ABFC758-EB5D-4344-B355-63004F7B93B0Q38131790-6FB8A120-3073-4EE4-9C12-C723645C6990Q38153673-B10F8CDE-C56F-4D9D-A7DB-CA5211A2AB6DQ38249996-29FD586E-1012-47A5-A9D3-EC53047F2D79Q38831069-CF749EE9-4E5B-402F-AD79-2FFD04A11230Q38841682-8B2F26FC-B3AA-471D-A8CB-FAD66E6C7798
P2860
Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Changes in plasma copeptin, th ...... nd excess in healthy subjects.
@ast
Changes in plasma copeptin, th ...... nd excess in healthy subjects.
@en
Changes in plasma copeptin, th ...... nd excess in healthy subjects.
@nl
type
label
Changes in plasma copeptin, th ...... nd excess in healthy subjects.
@ast
Changes in plasma copeptin, th ...... nd excess in healthy subjects.
@en
Changes in plasma copeptin, th ...... nd excess in healthy subjects.
@nl
prefLabel
Changes in plasma copeptin, th ...... nd excess in healthy subjects.
@ast
Changes in plasma copeptin, th ...... nd excess in healthy subjects.
@en
Changes in plasma copeptin, th ...... nd excess in healthy subjects.
@nl
P2093
P356
P1476
Changes in plasma copeptin, th ...... and excess in healthy subjects
@en
P2093
Beat Müller
Gabor Szinnai
Joachim Struck
Kaspar Berneis
Nils G Morgenthaler
Ulrich Keller
P304
P356
10.1210/JC.2007-0232
P407
P577
2007-07-17T00:00:00Z